Acromegaly is caused by a growth-hormone-secreting pituitary adenoma. Mutations in the AIP gene predispose patients to young-onset pituitary adenomas that are resistant to somatostatin analogue therapy. Chalal et al. describe a potential mechanism by which AIP modulates responsiveness to somatostatin analogues and identify PLAGL1 as a potential modulator of therapeutic activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Giustina, A. et al. A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95, 3141–3148 (2008).
Sherlock, M. et al. Mortality in patients with pituitary disease. Endocr. Rev. 31, 301–342 (2010).
Chalal, H. S. et al. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J. Clin. Endocrinol. Metab. http://dx.doi.org/10.1210/jc.2012-1111.
Lyons, J. et al. Two G protein oncogenes in human endocrine tumors. Science 249, 655–659 (1990).
Vierimaa, O. et al. Pituitary adenoma predisposition caused by germline mutation in the AIP gene. Science 312, 1228–1230 (2006).
Trivellin, G. & Korbonits, M. AIP and its interacting partners. J. Endocrinol. 210, 137–155 (2011).
Cazabat, L. et al. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. J. Clin. Endocrinol. Metab. 97, E663–E670 (2012).
Varrault, A. et al. Zac1 regulates an imprinted gene network critically involved in the control of embryonic growth. Dev. Cell 11, 711–722 (2006).
Pagotto, U. et al. The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res. 60, 6794–6799 (2000).
Theodoropoulou, M., Stalla, G. K. & Spengler, D. ZAC1 target genes and pituitary tumorigenesis. Mol. Cell. Endocrinol. 326, 60–65 (2010).
Acknowledgements
The authors wish to thank the Melvin Burkhardt Chair in Neurosurgical Oncology and the Karen Colina Wilson Research endowment in the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center at the Cleveland Clinic.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Marko, N., Weil, R. New pathways in the pathogenesis of pituitary adenomas. Nat Rev Endocrinol 8, 572–573 (2012). https://doi.org/10.1038/nrendo.2012.143
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2012.143
This article is cited by
-
mTOR promotes pituitary tumor development through activation of PTTG1
Oncogene (2017)
-
CUL4A is overexpressed in human pituitary adenomas and regulates pituitary tumor cell proliferation
Journal of Neuro-Oncology (2014)